<DOC>
	<DOC>NCT00347399</DOC>
	<brief_summary>The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.</brief_summary>
	<brief_title>Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration</brief_title>
	<detailed_description>The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after photodynamic therapy with verteporfin</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR) Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>macular degeneration</keyword>
	<keyword>antibodies</keyword>
	<keyword>angiogenesis inhibitor</keyword>
</DOC>